Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2025
0
Period ended Dec 31, 2025
Change on a year earlier
-100.0%
180 in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | -100.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 180 | -74.6% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 710 | +0.6% | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| FY2022 | Dec 31, 2022 | 706 | -14.4% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 825 | -1.6% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 838 | +1.0% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 830 | -7.1% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 893 | +9.0% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 819 | +6.9% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 766 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up simponi (golimumab — immunology, legacy ex-u.s. marketing rights) — worldwide sales ($m)
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M)0 · FY2025
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — International sales ($M)0 · FY2025
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%)-23.0% · FY2024
- Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide constant-currency (ex-exchange) growth YoY (%)-6.0% · FY2021
Cite this data
StockData. (2026). Merck Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_simponi
See every metric in the Merck KPI table. Data updated Oct 26, 2026.